RA Capital Makes Massive $100M Purchase in Artiva Biotherapeutics
ARTV has more than doubled off its 52-week low of $1.47.
Summary
RA Capital, a major institutional investor and director, made a substantial $100 million purchase of Artiva Biotherapeutics stock and warrants at the offering price of $11.52, signaling strong confidence following the company's recent $300 million public offering.
Key Events · Ownership and Investor Activity · ARTV
-
Significant Insider Purchase
RA Capital, a 10% owner and director, acquired $99,999,765 worth of common stock and pre-funded warrants on May 11, 2026.
-
Participation in Public Offering
This purchase was made at the offering price of $11.52 per share/warrant, following the company's $300 million public offering on May 8, 2026.
-
Strong Vote of Confidence
The substantial investment, representing 38.5% of the company's market capitalization, signals strong conviction from a major institutional investor and board member.
-
Premium to Current Market
The purchase price of $11.52 is above the current stock price of $10.29, indicating confidence in the company's valuation.
Analysis · ARTV · Life Sciences
This Form 4 reveals a massive vote of confidence from RA Capital, a significant institutional investor and board member, who purchased nearly $100 million in Artiva Biotherapeutics shares and pre-funded warrants. This transaction, occurring just days after the company's $300 million public offering, demonstrates RA Capital's strong conviction in the company's future, especially as the purchase price of $11.52 per share/warrant is above the current market price. Such a substantial investment, representing 38.5% of the company's market cap, significantly bolsters the company's capital position and investor sentiment following the recent capital raise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTV was trading at $10.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $259.5M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.